The developed drug 15K significantly inhibits the oncogenic kinase PAK1 and shows inhibitory effects on different PAK1-dependent biological activities including anti-cancer, anti-inflammatory, anti-angiogenic effects, and longevity extension activities in C. elegans9, 12, 13. This evidence concerns the gene PAK1 and cancer.